Epitan resumes sustained release trial

By Renate Krelle
Tuesday, 06 July, 2004

Melbourne-based EpiTan (ASX:EPT) has resumed its trial of the sustained release implant for tanning drug Melanotan.

The trial is being conducted at Queensland's Clive Berghofer Cancer Research Centre with a new significantly smaller solid injectable. It will be used to determine the optimal dose for the final commercial formulation of Melanotan.

Epitan executive chairman Dr Wayne Millen said the new implant was able to be injected with a 16 gauge needle.

Fast-aging placentas may contribute to pre-eclampsia

Placentas affected by pre-eclampsia show several signs of accelerated aging, including increased...

BioNTech opens mRNA manufacturing facility at La Trobe

Offering state-subsidised access to researchers and biotech startups, the facility aims to enable...

Personalised melanoma vaccine cuts risk of recurrence

Adding a personalised, mRNA-based cancer vaccine to standard immunotherapy after surgery for...

Content from other channels on our network

Closing the sensory gap with no- and low-alcohol wine

Balancing Food Safety, Traceability and Growth in a Changing Manufacturing Environment

Electrical technique for dehydrating milk, without heat

Ballarat food manufacturer plans to expand with new facility

$70m facility to strengthen local packaging production

Opinion: Why the role of continuous glucose monitors is expanding rapidly in primary health care

What the RACGP 6th edition means for cleaning in general practice

Smart bedding targets falls risk in aged care

Calvary confirms some services across two hospitals "will not be offered"

Opinion: Beyond connectivity — making health data meaningful across systems

AirTrunk and European Energy to build renewables in the Hunter

Australian Vanadium secures funding for electrolyte manufacturing

SPEE3D launches Darwin manufacturing facility

Delorean finalises funding for Sydney renewable gas project

Accuris adds Australian legislation to Engineering Workbench